Edition:
United States

Aurobindo Pharma Ltd (ARBN.NS)

ARBN.NS on National Stock Exchange of India

606.75INR
28 Apr 2017
Change (% chg)

Rs-0.30 (-0.05%)
Prev Close
Rs607.05
Open
Rs610.00
Day's High
Rs623.35
Day's Low
Rs604.10
Volume
3,566,219
Avg. Vol
2,100,823
52-wk High
Rs895.00
52-wk Low
Rs604.10

Select another date:

Wed, Apr 19 2017

BRIEF-Aurobindo Pharma says US FDA issued form 483 with 6 observations for unit-III

* Clarifies on news item "US FDA issues 5-6 'largely procedural' observations to Aurobindo Pharma's Unit-III"

BRIEF-Aurobindo Pharma gets FDA nod for generic drug to treat HIV-1 infection

* Says Aurobindo Pharma receives USFDA approval for generic Epzicom tablets

BRIEF-Aurobindo Pharma gets USFDA nod for Meropenem injection

* Meropenem injection is a generic equivalent of Astrazeneca Pharma's Merrem injection

BRIEF-Aurobindo Pharma gets FDA nod for generic version of Reckitt Benckiser’s Mucinex DM tablets

* Says Aurobindo Pharma receives USFDA approval for guaifenesin and dextromethorphan hydrobromide

Aurobindo plans second U.S. plant as Trump calls for local production

MUMBAI Indian drugmaker Aurobindo Pharma plans to set up a factory in the United States for injectable products, it said on Friday, days after U.S. President Donald Trump called on pharmaceutical companies to make more drugs locally.

UPDATE 1-Aurobindo plans second U.S. plant as Trump calls for local production

MUMBAI, Feb 10 Indian drugmaker Aurobindo Pharma plans to set up a factory in the United States for injectable products, it said on Friday, days after U.S. President Donald Trump called on pharmaceutical companies to make more drugs locally.

India's Aurobindo eyes U.S. plant amid Trump push on jobs

MUMBAI, Feb 10 Indian drugmaker Aurobindo Pharma said on Friday it was looking to set up a manufacturing facility for injectable products in the United States, days after President Donald Trump called on pharmaceutical companies to make more drugs locally.

India's Aurobindo shares hit nine-month low on US price-fixing lawsuit

MUMBAI Indian drugmaker Aurobindo Pharma Ltd's shares hit their lowest in more than nine months on Friday after the company was named in a lawsuit alleging it colluded with other drugmakers to fix prices of two commonly used drugs in the United States.

BRIEF-Aurobindo Pharma unit Arrow Generiques to buy select assets in France from Teva

* Aurobindo Pharma Ltd says Arrow Generiques to acquire select assets in France from Teva

BRIEF-India's Aurobindo Pharma Q2 consol net profit rises 33.5 pct

* Sept quarter consol net profit 6.06 billion rupees Source text for Eikon: http://bit.ly/2fS1r1x Further company coverage: (Reporting by Promit Mukherjee)

Select another date:

More From Around the Web